Summary

Global blood plasma & plasma derived medicinal Products market is expected to reach USD 62.66 billion by 2032 from USD 34.88 billion in 2024, growing at a CAGR of 7.65% during the forecast period of 2025 to 2032.

Market Segmentation:
Global Blood Plasma & Plasma Derived Medicinal Products Market, By Product (Immunoglobulins, Coagulation Factors (For Bleeding Disorders), Albumin (Plasma Volume Expander), Protease Inhibitors (For Genetic Deficiencies), Monoclonal Antibodies (Derived From Plasma Cells), and Other Plasma Derived Proteins), Application (Immunology, Hematology, Critical Care, Neurology, Pulmonology, Haemato-Oncology, Rheumatology, and Other Applications), Processing Technology (Ion Exchange Chromatography, Affinity Chromatography, Cryoprecipitation, Ultrafiltration, and Microfiltration), Mode (Modern and Traditional Plasma Fractionation), End-User (Hospitals & Clinics, Research Labs, Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Poland, Denmark, Sweden, Belgium, Ireland, Norway, Finland, Rest of Europe, China, Japan, South Korea, Australia, India, Malaysia, Thailand, Singapore, Philippines, Indonesia, New Zealand, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Columbia, Chile, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Bahrain, Kuwait, Oman, Qatar, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2032
Overview of the Global Blood Plasma & Plasma Derived Medicinal Market Dynamics:
Drivers
• Rising prevalence of rare and chronic diseases
• Expanding geriatric population
Restraints
• High cost and complex manufacturing process
• Lack of plasma supply and donor
Opportunities
• Advancements in plasma processing technologies to enhance yield and reduce costs
• Reimbursement frameworks and increased governmental focus on rare disease treatment
Market Players:
The key players operating in the global blood plasma & plasma derived medicinal products market are:
• CSL
• Takeda Pharmaceutical Company Limited
• Grifols, S.A.
• Octapharma AG
• Kedrion
• ADMA Biologics, Inc
• Aegros
• Bharat Serums
• Biotest AG
• Fresenius Kabi AG
• GC Biopharma corporate
• ICHOR
• Intas Pharmaceuticals Ltd.
• Kamada Pharmaceuticals
• KM Biologics
• LFB
• PlasmaGen BioSciences Pvt. Ltd.
• Proliant Health & Biologicals
• Promea
• Reliance Life Sciences
• Sichuan Yuanda Shyuang Pharmaceutical Co., Ltd.
• SK Plasma
• Synthaverse S. A.
• Taibang Bio Group Co., Ltd
• VIRCHOW BIOTECH

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 90
1.1 OBJECTIVES OF THE STUDY 90
1.2 MARKET DEFINITION 90
1.3 OVERVIEW OF THE GLOBAL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET 90
1.4 LIMITATIONS 92
1.5 MARKETS COVERED 93
2 MARKET SEGMENTATION 96
2.1 MARKETS COVERED 96
2.2 GEOGRAPHICAL SCOPE 97
2.3 YEARS CONSIDERED FOR THE STUDY 98
2.4 CURRENCY AND PRICING 98
2.5 DBMR TRIPOD DATA VALIDATION MODEL 99
2.6 MULTIVARIATE MODELLING 102
2.7 PRODUCT LIFELINE CURVE 102
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 103
2.9 DBMR MARKET POSITION GRID 104
2.10 MARKET END USER COVERAGE GRID 105
2.11 VENDOR SHARE ANALYSIS 106
2.12 SECONDARY SOURCES 107
2.13 ASSUMPTIONS 107
3 EXECUTIVE SUMMARY 108
4 PREMIUM INSIGHTS 114
4.1 PESTLE ANALYSIS 116
4.1.1 POLITICAL FACTORS 116
4.1.2 ECONOMIC FACTORS 116
4.1.3 SOCIAL FACTORS 116
4.1.4 TECHNOLOGICAL FACTORS 117
4.1.5 ENVIRONMENTAL FACTORS 117
4.1.6 LEGAL FACTORS 117
4.2 PORTER’S FIVE FORCES 118
4.2.1 THREAT OF NEW ENTRANTS 118
4.2.2 BARGAINING POWER OF SUPPLIERS 118
4.2.3 BARGAINING POWER OF BUYERS 119
4.2.4 THREAT OF SUBSTITUTES 119
4.2.5 INDUSTRY RIVALRY 119
4.3 SUPPLY CHAIN IMPACT ON THE GLOBAL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET 120
4.3.1 OVERVIEW 120
4.3.2 RAW MATERIAL AVAILABILITY 120
4.3.3 MANUFACTURING CAPACITY 120
4.3.4 LOGISTICS AND LAST-MILE HURDLES 120
4.3.5 PRICING MODELS AND MARKET POSITIONING 121
4.4 INNOVATION STRATEGIES 122
4.4.1 KEY INNOVATION STRATEGIES 122
4.4.2 EMERGING DELIVERY TECHNIQUES 123
4.4.3 STRATEGIC IMPLICATIONS 123
4.4.4 CONCLUSION 123
4.5 RISK AND MITIGATION 124
4.6 VENDOR SELECTION DYNAMICS 126
4.6.1 PRODUCT QUALITY AND REGULATORY COMPLIANCE 126
4.6.2 SUPPLY CHAIN CAPABILITIES AND RELIABILITY 126
4.6.3 CLINICAL EFFICACY AND INNOVATION 126
4.6.4 COST COMPETITIVENESS AND REIMBURSEMENT COMPATIBILITY 126
4.6.5 LOCAL MARKET PRESENCE AND SUPPORT INFRASTRUCTURE 126
4.6.6 ETHICAL SOURCING, ESG COMPLIANCE, AND TRANSPARENCY 127
4.6.7 CONCLUSION 127
4.7 TARIFFS AND THEIR IMPACT ON MARKET 128
4.7.1 CURRENT TARIFF RATES IN TOP-5 COUNTRY MARKETS 128
4.7.2 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE 128
4.7.3 VENDOR SELECTION CRITERIA DYNAMICS 128
4.7.4 IMPACT ON SUPPLY CHAIN 129
4.7.5 IMPACT ON PRICES 129
4.7.6 REGULATORY INCLINATION 129
4.7.6.1 GCC TRADE ALIGNMENT & FTAS 129
4.7.6.2 SPECIAL ZONES AND RE-EXPORT MODELS 129
4.7.6.3 LOCAL SUBSIDY & POLICY RESPONSE 129
4.7.6.4 DOMESTIC COURSE OF CORRECTION 129
5 REGULATION COVERAGE 131
6 MARKET OVERVIEW 134
6.1 DRIVERS 136
6.1.1 RISING PREVALENCE OF RARE AND CHRONIC DISEASES 136
6.1.2 EXPANDING GERIATRIC POPULATION 136
6.1.3 TECHNOLOGICAL ADVANCEMENTS IN PLASMA FRACTIONATION 137
6.1.4 GOVERNMENT AND INSTITUTIONAL SUPPORT 138
6.2 RESTRAINTS 139
6.2.1 HIGH COST AND COMPLEX MANUFACTURING PROCESS 139
6.2.2 LACK OF PLASMA SUPPLY AND DONOR 139
6.3 OPPORTUNITIES 140
6.3.1 ADVANCEMENTS IN PLASMA PROCESSING TECHNOLOGIES TO ENHANCE YIELD AND REDUCE COSTS 140
6.3.2 REIMBURSEMENT FRAMEWORKS AND INCREASED GOVERNMENTAL FOCUS ON RARE DISEASE TREATMENT 141
6.3.3 STRATEGIC ALLIANCES, MERGERS, AND ACQUISITIONS TO STRENGTHEN GLOBAL MARKET PENETRATION 142
6.4 CHALLENGES 143
6.4.1 COMPETITIVE PRESSURE FROM RECOMBINANT AND ALTERNATIVE BIOLOGICAL THERAPIES 143
6.4.2 INFRASTRUCTURE LIMITATIONS IN COLD CHAIN LOGISTICS IMPACTING PRODUCT DISTRIBUTION 143
7 GLOBAL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT 145
7.1 OVERVIEW 146
7.2 IMMUNOGLOBULINS 149
7.3 COAGULATION FACTORS (FOR BLEEDING DISORDERS) 151
7.4 ALBUMIN (PLASMA VOLUME EXPANDER) 156
7.5 PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) 157
7.6 MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) 159
7.7 OTHER PLASMA DERIVED PROTEINS 160
8 GLOBAL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION 162
8.1 OVERVIEW 163
8.2 IMMUNOLOGY 166
8.3 HEMATOLOGY 166
8.4 CRITICAL CARE 167
8.5 NEUROLOGY 167
8.6 PULMONOLOGY 168
8.7 HAEMATO-ONCOLOGY 168
8.8 RHEUMATOLOGY 169
8.9 OTHER APPLICATIONS 169
9 GLOBAL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TECHNOLOGY 170
9.1 OVERVIEW 171
9.2 ION EXCHANGE CHROMATOGRAPHY 174
9.3 AFFINITY CHROMATOGRAPHY 174
9.4 CRYOPRECIPITATION 175
9.5 ULTRAFILTRATION 175
9.6 MICROFILTRATION 176
10 GLOBAL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE 177
10.1 OVERVIEW 178
10.2 MODERN 181
10.3 TRADITIONAL PLASMA FRACTIONATION 181
11 GLOBAL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER 182
11.1 OVERVIEW 183
11.2 HOSPITALS & CLINICS 186
11.3 RESEARCH LABS 186
11.4 ACADEMIC INSTITUTES 187
11.5 OTHERS 187
12 GLOBAL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL 188
12.1 OVERVIEW 189
12.2 DIRECT TENDERS 192
12.3 THIRD PARTY DISTRIBUTORS 192
12.4 OTHERS 193
13 GLOBAL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION 194
13.1 OVERVIEW 195
13.2 NORTH AMERICA 198
13.2.1 U.S 208
13.2.2 CANADA 218
13.2.3 MEXICO 228
13.3 EUROPE 238
13.3.1 GERMANY 249
13.3.2 FRANCE 258
13.3.3 U.K 267
13.3.4 ITALY 276
13.3.5 SPAIN 285
13.3.6 RUSSIA 294
13.3.7 TURKEY 303
13.3.8 NETHERLANDS 312
13.3.9 SWITZERLAND 321
13.3.10 POLAND 330
13.3.11 DENMARK 339
13.3.12 SWEDEN 348
13.3.13 BELGIUM 357
13.3.14 IRELAND 365
13.3.15 NORWAY 373
13.3.16 FINLAND 381
13.3.17 REST OF EUROPE 389
13.4 ASIA-PACIFIC 390
13.4.1 CHINA 401
13.4.2 JAPAN 410
13.4.3 SOUTH KOREA 419
13.4.4 AUSTRALIA 428
13.4.5 INDIA 437
13.4.6 MALAYSIA 446
13.4.7 THAILAND 455
13.4.8 SINGAPORE 464
13.4.9 PHILIPPINES 473
13.4.10 INDONESIA 482
13.4.11 NEW ZEALAND 491
13.4.12 VIETNAM 500
13.4.13 TAIWAN 508
13.4.14 REST OF ASIA-PACIFIC 516
13.5 MIDDLE EAST AND AFRICA 517
13.5.1 SOUTH AFRICA 527
13.5.2 SAUDI ARABIA 536
13.5.3 U.A.E. 545
13.5.4 ISRAEL 554
13.5.5 EGYPT 563
13.5.6 BAHRAIN 571
13.5.7 KUWAIT 580
13.5.8 OMAN 588
13.5.9 QATAR 596
13.5.10 REST OF MIDDLE EAST AND AFRICA 604
13.6 SOUTH AMERICA 605
13.6.1 BRAZIL 616
13.6.2 ARGENTINA 625
13.6.3 COLUMBIA 634
13.6.4 CHILE 643
13.6.5 PERU 651
13.6.6 REST OF SOUTH AMERICA 659
14 GLOBAL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, COMPANY LANDSCAPE 660
14.1 COMPANY SHARE ANALYSIS: GLOBAL 660
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 661
14.3 COMPANY SHARE ANALYSIS: EUROPE 662
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 663
15 SWOT ANALYSIS 664
16 COMPANY PROFILE 665
16.1 CSL 665
16.1.1 COMPANY SNAPSHOT 665
16.1.2 REVENUE ANALYSIS 665
16.1.3 COMPANY SHARE ANALYSIS 666
16.1.4 PRODUCT PORTFOLIO 666
16.1.5 RECENT DEVELOPMENTS 667
16.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED 668
16.2.1 COMPANY SNAPSHOT 668
16.2.2 REVENUE ANALYSIS 669
16.2.3 COMPANY SHARE ANALYSIS 669
16.2.4 PRODUCT PORTFOLIO 670
16.2.5 RECENT DEVELOPMENTS 670
16.3 GRIFOLS, S.A. 671
16.3.1 COMPANY SNAPSHOT 671
16.3.2 REVENUE ANALYSIS 671
16.3.3 COMPANY SHARE ANALYSIS 672
16.3.4 PRODUCT PORTFOLIO 672
16.3.5 RECENT DEVELOPMENTS 674
16.4 OCTAPHARMA AG 675
16.4.1 COMPANY SNAPSHOT 675
16.4.2 COMPANY SHARE ANALYSIS 675
16.4.3 PRODUCT PORTFOLIO 676
16.4.4 RECENT DEVELOPMENTS 678
16.5 KEDRION 679
16.5.1 COMPANY SNAPSHOT 679
16.5.2 COMPANY SHARE ANALYSIS 679
16.5.3 PRODUCT PORTFOLIO 680
16.5.4 RECENT DEVELOPMENT 680
16.6 ADMA BIOLOGICS, INC 681
16.6.1 COMPANY SNAPSHOT 681
16.6.2 REVENUE ANALYSIS 681
16.6.3 PRODUCT PORTFOLIO 682
16.6.4 RECENT DEVELOPMENT 682
16.7 AEGROS 683
16.7.1 COMPANY SNAPSHOT 683
16.7.2 PRODUCT PORTFOLIO 683
16.7.3 RECENT DEVELOPMENT 683
16.8 BHARAT SERUMS 684
16.8.1 COMPANY SNAPSHOT 684
16.8.2 PRODUCT PORTFOLIO 684
16.8.3 RECENT DEVELOPMENT 684
16.9 BIOTEST AG. 685
16.9.1 COMPANY SNAPSHOT 685
16.9.2 REVENUE ANALYSIS 685
16.9.3 PRODUCT PORTFOLIO 686
16.9.4 RECENT DEVELOPMENTS 688
16.10 FRESENIUS KABI AG 689
16.10.1 COMPANY SNAPSHOT 689
16.10.2 PRODUCT PORTFOLIO 689
16.10.3 RECENT DEVELOPMENT 689
16.11 GC BIOPHARMA CORPORATE 690
16.11.1 COMPANY SNAPSHOT 690
16.11.2 REVENUE ANALYSIS 690
16.11.3 PRODUCT PORTFOLIO 691
16.11.4 RECENT DEVELOPMENT 692
16.12 ICHOR 693
16.12.1 COMPANY SNAPSHOT 693
16.12.2 PRODUCT PORTFOLIO 693
16.12.3 RECENT DEVELOPMENT 697
16.13 INTAS PHARMACEUTICALS LTD. 698
16.13.1 COMPANY SNAPSHOT 698
16.13.2 PRODUCT PORTFOLIO 698
16.13.3 RECENT DEVELOPMENT 698
16.14 KAMADA PHARMACEUTICALS 699
16.14.1 COMPANY SNAPSHOT 699
16.14.2 REVENUE ANALYSIS 699
16.14.3 PRODUCT PORTFOLIO 700
16.14.4 RECENT DEVELOPMENT 701
16.15 KM BIOLOGICS 702
16.15.1 COMPANY SNAPSHOT 702
16.15.2 PRODUCT PORTFOLIO 702
16.15.3 RECENT DEVELOPMENT 702
16.16 LFB 703
16.16.1 COMPANY SNAPSHOT 703
16.16.2 PRODUCT PORTFOLIO 703
16.16.3 RECENT DEVELOPMENT 705
16.17 PLASMAGEN BIOSCIENCES PVT. LTD. 706
16.17.1 COMPANY SNAPSHOT 706
16.17.2 PRODUCT PORTFOLIO 706
16.17.3 RECENT DEVELOPMENTS 708
16.18 PROLIANT HEALTH & BIOLOGICALS 709
16.18.1 COMPANY SNAPSHOT 709
16.18.2 PRODUCT PORTFOLIO 709
16.18.3 RECENT DEVELOPMENT 709
16.19 PROMEA 710
16.19.1 COMPANY SNAPSHOT 710
16.19.2 PRODUCT PORTFOLIO 710
16.19.3 RECENT DEVELOPMENT 711
16.20 RELIANCE LIFE SCIENCES 712
16.20.1 COMPANY SNAPSHOT 712
16.20.2 BUSINESS PORTFOLIO 712
16.20.3 RECENT DEVELOPMENT 713
16.21 SICHUAN YUANDA SHYUANG PHARMACEUTICAL CO., LTD. 714
16.21.1 COMPANY SNAPSHOT 714
16.21.2 PRODUCT PORTFOLIO 714
16.21.3 RECENT DEVELOPMENT 715
16.22 SK PLASMA 716
16.22.1 COMPANY SNAPSHOT 716
16.22.2 PRODUCT PORTFOLIO 716
16.22.3 RECENT DEVELOPMENT 717
16.23 SYNTHAVERSE S. A. 718
16.23.1 COMPANY SNAPSHOT 718
16.23.2 REVENUE ANALYSIS 719
16.23.3 PRODUCT PORTFOLIO 719
16.23.4 RECENT DEVELOPMENTS 720
16.24 TAIBANG BIO GROUP CO., LTD 721
16.24.1 COMPANY SNAPSHOT 721
16.24.2 PRODUCT PORTFOLIO 721
16.24.3 RECENT DEVELOPMENT 721
16.25 VIRCHOW BIOTECH 722
16.25.1 COMPANY SNAPSHOT 722
16.25.2 PRODUCT PORTFOLIO 722
16.25.3 RECENT DEVELOPMENT 724
17 QUESTIONNAIRE 725
18 RELATED REPORTS 728